Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Livzon Pharmaceutical Group ( (HK:1513) ) just unveiled an announcement.
Livzon Pharmaceutical Group has adjusted its board succession plan by withdrawing an earlier proposal to appoint Vice President Liu Daping as an executive director in the 11th board session, instead nominating him for the 12th board session to align with the upcoming board election and improve governance continuity. The company’s board, following a recommendation from its nomination committee, will seek shareholder approval at the annual general meeting to confirm Liu’s appointment, which would run from the meeting date through the end of the 12th board’s term and leverage his extensive management experience across several Chinese pharmaceutical manufacturers.
The decision underscores Livzon’s effort to optimize its corporate governance structure and ensure an orderly transition as it forms the next board. Liu, 39, currently vice president and director at key group subsidiaries, brings a background in pharmaceutics and nearly 14 years of operational leadership in production and general management roles at various pharma firms, positioning him as a significant addition to the company’s senior leadership team.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a Chinese pharmaceutical company focused on developing, manufacturing and marketing drug products, supported by in-house research institutes and production facilities. The group operates through multiple subsidiaries, with activities spanning pharmaceutical R&D, formulation production and broader industrial operations in the healthcare sector.
Average Trading Volume: 914,703
Technical Sentiment Signal: Buy
Current Market Cap: HK$31.41B
See more data about 1513 stock on TipRanks’ Stock Analysis page.